share_log

ADC Therapeutics SA's (NYSE:ADCT) Stock Price Dropped 22% Last Week; Individual Investors Would Not Be Happy

ADC Therapeutics SA's (NYSE:ADCT) Stock Price Dropped 22% Last Week; Individual Investors Would Not Be Happy

ADC Therapeutics SA(紐約證券交易所代碼:ADCT)的股價上週下跌了22%;個人投資者不會感到高興
Simply Wall St ·  03/14 21:27

Key Insights

關鍵見解

  • ADC Therapeutics' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • The top 7 shareholders own 52% of the company
  • Institutional ownership in ADC Therapeutics is 15%
  • ADC Therapeutics擁有大量個人投資者的所有權,這表明關鍵決策受廣大公衆股東的影響
  • 前7名股東擁有公司52%的股份
  • ADC Therapeutics的機構所有權爲15%

A look at the shareholders of ADC Therapeutics SA (NYSE:ADCT) can tell us which group is most powerful. The group holding the most number of shares in the company, around 27% to be precise, is individual investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

看看ADC Therapeutics SA(紐約證券交易所代碼:ADCT)的股東可以告訴我們哪個集團最強大。持有公司股份最多的集團是個人投資者,準確地說約爲27%。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

And following last week's 22% decline in share price, individual investors suffered the most losses.

繼上週股價下跌22%之後,個人投資者遭受的損失最大。

In the chart below, we zoom in on the different ownership groups of ADC Therapeutics.

在下圖中,我們放大了ADC Therapeutics的不同所有權群體。

ownership-breakdown
NYSE:ADCT Ownership Breakdown March 14th 2024
紐約證券交易所:ADCT 所有權明細 2024 年 3 月 14 日

What Does The Institutional Ownership Tell Us About ADC Therapeutics?

關於ADC療法,機構所有權告訴我們什麼?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構根據近似於當地市場的指數來衡量自己的表現。因此,他們通常會更多地關注主要指數中包含的公司。

We can see that ADC Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see ADC Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.

我們可以看到,ADC Therapeutics確實有機構投資者;他們持有該公司很大一部分股票。這表明專業投資者有一定的信譽。但是我們不能僅僅依靠這個事實,因爲機構有時會像所有人一樣進行不良投資。當多家機構擁有一隻股票時,總是存在處於 “擁擠交易” 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到ADC Therapeutics的歷史收益和收入,但請記住,故事總是有更多內容。

earnings-and-revenue-growth
NYSE:ADCT Earnings and Revenue Growth March 14th 2024
紐約證券交易所:ADCT收益和收入增長 2024年3月14日

It would appear that 27% of ADC Therapeutics shares are controlled by hedge funds. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. The company's largest shareholder is Redmile Group, LLC, with ownership of 19%. Meanwhile, the second and third largest shareholders, hold 9.2% and 8.0%, of the shares outstanding, respectively.

看來ADC Therapeutics有27%的股票由對沖基金控制。這值得注意,因爲對沖基金通常是非常活躍的投資者,他們可能會試圖影響管理層。許多人希望在短期或中期內看到價值創造(以及更高的股價)。該公司的最大股東是Redmile Group, LLC,其所有權爲19%。同時,第二和第三大股東分別持有已發行股份的9.2%和8.0%。

We did some more digging and found that 7 of the top shareholders account for roughly 52% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

我們進一步挖掘發現,大股東中有7人約佔登記冊的52%,這意味着除了較大的股東外,還有一些較小的股東,從而在一定程度上平衡了彼此的利益。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。有很多分析師在報道該股,因此可能也值得一看他們的預測。

Insider Ownership Of ADC Therapeutics

ADC Therapeutics的內部所有權

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

儘管內部人士的確切定義可能是主觀的,但幾乎每個人都認爲董事會成員是內部人士。公司管理層經營業務,但首席執行官將對董事會負責,即使他或她是董事會成員。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

Our most recent data indicates that insiders own some shares in ADC Therapeutics SA. In their own names, insiders own US$31m worth of stock in the US$359m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

我們的最新數據顯示,內部人士擁有ADC Therapeutics SA的部分股份。內部人士以自己的名義擁有這家價值3.59億美元的公司價值3100萬美元的股票。有人會說,這表明股東和董事會之間的利益一致。但是,可能值得檢查一下這些內部人士是否一直在出售。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 27% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散戶投資者在內的公衆擁有該公司27%的股份,因此不容易被忽視。這種所有權規模雖然可觀,但如果決定與其他大股東不同步,可能不足以改變公司的政策。

Private Equity Ownership

私募股權所有權

With an ownership of 5.1%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

私募股權公司擁有5.1%的所有權,可以在制定以價值創造爲重點的企業戰略方面發揮作用。有時我們會看到私募股權長期存在,但總的來說,它們的投資期限較短,而且顧名思義,對上市公司的投資並不多。一段時間後,他們可能會考慮出售資本並將資本重新部署到其他地方。

Private Company Ownership

私人公司所有權

We can see that Private Companies own 12%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我們可以看到,私人公司擁有12%的已發行股份。可能值得對此進行更深入的研究。如果關聯方,例如內部人士,對其中一傢俬營公司有興趣,則應在年度報告中披露。私營公司也可能在公司中擁有戰略利益。

Public Company Ownership

上市公司所有權

Public companies currently own 5.0% of ADC Therapeutics stock. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

上市公司目前擁有ADC Therapeutics5.0%的股票。我們無法確定,但這很可能是一個戰略利益。這些企業可能相似,也可以合作。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 3 warning signs for ADC Therapeutics you should be aware of, and 2 of them make us uncomfortable.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。一個很好的例子:我們發現了你應該注意的三種ADC Therapeutics警告信號,其中兩個讓我們感到不舒服。

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果你像我一樣,你可能需要考慮這家公司是會成長還是會萎縮。幸運的是,您可以查看這份免費報告,其中顯示了分析師對其未來的預測。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論